Utama › Leukemia Mieloid Akut › Arkansas › Little Rock
Kajian klinikal Leukemia Mieloid Akut di Little Rock, AR
13 kajian untuk Leukemia Mieloid Akut sedang mencari peserta di lokasi dalam dan sekitar Little Rock (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.
Teks kajian rasmi (Bahasa Inggeris)
Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Mengambil pesertaFasa 2
- University of Arkansas for Medical Sciences, Little Rock
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
- CARTI Cancer Center, Little Rock
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
Mengambil pesertaFasa 2
- University of Arkansas for Medical Sciences, Little Rock
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
Mengambil pesertaFasa 3
- University of Arkansas at Little Rock, Little Rock
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
Mengambil pesertaFasa 2
- University of Arkansas for Medical Sciences, Little Rock
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
Mengambil pesertaFasa 2
- University of Arkansas for Medical Sciences, Little Rock
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
Mengambil pesertaFasa 2
- University of Arkansas for Medical Sciences, Little Rock
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
Mengambil pesertaFasa 3
- Arkansas Children's Hospital, Little Rock
Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia
Mengambil pesertaFasa 3
- Arkansas Children's Hospital, Little Rock
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
Mengambil pesertaFasa 1/2
- Arkansas Children's Hospital, Little Rock
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
Mengambil pesertaFasa 3
- Arkansas Children's Hospital, Little Rock
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Mengambil pesertaKajian pemerhatian
- Arkansas Children's Hospital, Little Rock
Study of Talazoparib in Combination With Chemotherapy in Relapsed Pediatric AML to Determine Safety and Efficacy
Mengambil pesertaFasa 1
- Arkansas Children's Hospital, Little Rock
Kajian Leukemia Mieloid Akut di bandar lain
- Houston, TX85 kajian
- New York City, NY51 kajian
- Boston, MA44 kajian
- Seattle, WA41 kajian
- Baldwin Park, CA40 kajian
- Columbus, OH35 kajian
- Philadelphia, PA34 kajian
- Durham, NC33 kajian
- Atlanta, GA31 kajian
- Tampa, FL29 kajian
- Chicago, IL26 kajian
- Portland, OR25 kajian
Kajian lain di Little Rock
- Skizofrenia19 kajian
- Kanser (semua jenis)14 kajian
- Gangguan Depresi Major14 kajian
- Kanser Paru-paru Bukan Sel Kecil13 kajian
- Obesiti11 kajian
- Kanser Endometrium10 kajian
- Depresi10 kajian
- Diabetes Jenis 210 kajian
- Kanser Paru-paru9 kajian
- Penyakit Kardiovaskular9 kajian
- Kanser Pundi Kencing9 kajian
- Kegagalan Jantung9 kajian
Daripada ClinicalTrials.gov, data diperoleh pada 6 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.